Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference
08 April 2022 - 3:00PM
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of primary and metastatic cancers
of the liver, will participate in the Canaccord Genuity Horizons in
Oncology Conference:
- Date: April 14, 2022
at 3:00 PM ET
- Format: Fireside
Chat
- Webcast
link: https://wsw.com/webcast/canaccord74/dcth/2433851
Management will be participating in virtual
one-on-one meetings throughout the event. To arrange a meeting with
management, please contact your conference representative or
James@HaydenIR.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology
company focused on the treatment of primary and metastatic liver
cancers. The company’s proprietary percutaneous hepatic perfusion
(PHP) system is designed to administer high-dose chemotherapy to
the liver while controlling systemic exposure and associated side
effects. In the United States, the PHP system is being developed
under the tradename HEPZATO KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, for the treatment
of metastatic ocular melanoma (mOM), also known as metastatic uveal
melanoma (mUM) and is considered a combination drug and device
product regulated by the United States Food and Drug Administration
(FDA).
In Europe, the PHP system is now regulated as a
Class lll medical device and is approved for sale under the trade
name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT,
where it has been used at major medical centers to treat a wide
range of cancers of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James
Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024